New-Onset Vitiligo Following Etanercept for Ankylosing Spondylitis

Carly Dunn, Stacy L. McMurray, Allison Jones, Debendra Pattanaik

Abstract

Tumor Necrosis Factor-alpha (TNF-a) inhibitors, are used widely to treat a variety of chronic inflammatory conditions such as ankylosing spondylitis, Crohn’s disease, rheumatoid arthritis, and psoriasis. Recently, there has been an increase in the number of reports of immune-mediated skin diseases, such as lichen planus, psoriasis, granuloma annulare, following the initiation of TNF-a inhibitors. We present a patient with ankylosing spondylitis previously treated with adalimumab who developed vitiligo shortly after switching to etanercept to achieve better control of his joint disease.